Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry

Overview

Journal Mini Rev Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2010 Apr 8

PMID 20370702

Citations 50

Authors

Subhash Padhye

Deepak Chavan

Shubhangini Pandey

Jyoti Deshpande

K Venkateswara Swamy

Fazlul H Sarkar

Affiliations

Soon will be listed here.

Abstract

Curcumin is a natural polyphenol derived from the plant Curcuma longa, commonly called turmeric. Extensive research over past 50 years has indicated that this polyphenol is highly pleiotropic molecule capable of preventing and treating various cancers. The anticancer potential of Curcumin is severely affected by its limited systemic and target tissue bioavailability and rapid metabolism. In the present review article, we provide a summarized account of different drug delivery systems employed for tackling the problem of cucumin's bioavailability such as liposomes, phospholipid complexes and nanoparticles. Concomitantly we have reviewed the large volume of literature reports describing structural modifications of Curcumin and the anticancer potential of its analogs. Some of the difluorocurcumin analogs allowing longer circulation times and preferential accumulation in the pancreas seem to offer promising leads for conducting first in-depth animal studies and subsequently clinical trials for the use of these analogs for prevention of tumor progression and/or treatments of human malignancies.

Citing Articles

A Review of Recent Curcumin Analogues and Their Antioxidant, Anti-Inflammatory, and Anticancer Activities.

Kaur K, Al-Khazaleh A, Bhuyan D, Li F, Li C Antioxidants (Basel). 2024; 13(9).

PMID: 39334750 PMC: 11428508. DOI: 10.3390/antiox13091092.

Diastereoselective synthesis of highly substituted cyclohexanones and tetrahydrochromene-4-ones via conjugate addition of curcumins to arylidenemalonates.

Nair D, Tiwari A, Laha B, Namboothiri I Beilstein J Org Chem. 2024; 20:2016-2023.

PMID: 39161707 PMC: 11331540. DOI: 10.3762/bjoc.20.177.

Exploring the therapeutic mechanism of curcumin in prostate cancer using network pharmacology and molecular docking.

Li J, Wang X, Xue L, He Q Heliyon. 2024; 10(12):e33103.

PMID: 39022084 PMC: 11253540. DOI: 10.1016/j.heliyon.2024.e33103.

Exploring the Targets and Molecular Mechanisms of Curcumin for the Treatment of Bladder Cancer Based on Network Pharmacology, Molecular Docking and Molecular Dynamics.

Li J, Feng S, Wang X, Zhang B, He Q Mol Biotechnol. 2024; .

PMID: 38822913 DOI: 10.1007/s12033-024-01190-x.

Can Compounds of Natural Origin Be Important in Chemoprevention? Anticancer Properties of Quercetin, Resveratrol, and Curcumin-A Comprehensive Review.

Cecerska-Heryc E, Wisniewska Z, Serwin N, Polikowska A, Goszka M, Engwert W Int J Mol Sci. 2024; 25(8).

PMID: 38674092 PMC: 11050349. DOI: 10.3390/ijms25084505.

References

Amolins M, Peterson L, Blagg B . Synthesis and evaluation of electron-rich curcumin analogues. Bioorg Med Chem. 2008; 17(1):360-7. PMC: 2753864. DOI: 10.1016/j.bmc.2008.10.057. View

Qiu X, Liu Z, Shao W, Liu X, Jing D, Yu Y . Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors. Bioorg Med Chem. 2008; 16(17):8035-41. DOI: 10.1016/j.bmc.2008.07.054. View

Chandru H, Sharada A, Bettadaiah B, Ananda Kumar C, Rangappa K, Sunila . In vivo growth inhibitory and anti-angiogenic effects of synthetic novel dienone cyclopropoxy curcumin analogs on mouse Ehrlich ascites tumor. Bioorg Med Chem. 2007; 15(24):7696-703. DOI: 10.1016/j.bmc.2007.08.051. View

Thomas S, Zhong D, Zhou W, Malik S, Liotta D, Snyder J . EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle. 2008; 7(15):2409-17. PMC: 2573855. DOI: 10.4161/cc.6410. View

Ohtsu H, Xiao Z, Ishida J, Nagai M, Wang H, Itokawa H . Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem. 2002; 45(23):5037-42. DOI: 10.1021/jm020200g. View

Shim J, Kim D, Jung H, Kim J, Lim D, Lee S . Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg Med Chem. 2002; 10(8):2439-44. DOI: 10.1016/s0968-0896(02)00116-5. View

Youssef K, El-Sherbeny M . Synthesis and antitumor activity of some curcumin analogs. Arch Pharm (Weinheim). 2005; 338(4):181-9. DOI: 10.1002/ardp.200400939. View

Hallgrimsson B, Donnabhain B, Blom D, Lozada M, Willmore K . Why are rare traits unilaterally expressed?: trait frequency and unilateral expression for cranial nonmetric traits in humans. Am J Phys Anthropol. 2005; 128(1):14-25. DOI: 10.1002/ajpa.20187. View

Kunnumakkara A, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal B . Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res. 2008; 14(7):2128-36. DOI: 10.1158/1078-0432.CCR-07-4722. View

10.

Shen L, Ji H . Theoretical study on physicochemical properties of curcumin. Spectrochim Acta A Mol Biomol Spectrosc. 2006; 67(3-4):619-23. DOI: 10.1016/j.saa.2006.08.018. View

11.

Mizushina Y, Ishidoh T, Takeuchi T, Shimazaki N, Koiwai O, Kuramochi K . Monoacetylcurcumin: a new inhibitor of eukaryotic DNA polymerase lambda and a new ligand for inhibitor-affinity chromatography. Biochem Biophys Res Commun. 2005; 337(4):1288-95. DOI: 10.1016/j.bbrc.2005.10.005. View

12.

Singh S, Aggarwal B . Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995; 270(42):24995-5000. DOI: 10.1074/jbc.270.42.24995. View

13.

Gafner S, Lee S, Cuendet M, Barthelemy S, Vergnes L, Labidalle S . Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry. 2004; 65(21):2849-59. DOI: 10.1016/j.phytochem.2004.08.008. View

14.

Tamvakopoulos C, Dimas K, Sofianos Z, Hatziantoniou S, Han Z, Liu Z . Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res. 2007; 13(4):1269-77. DOI: 10.1158/1078-0432.CCR-06-1839. View

15.

Padhye S, Yang H, Jamadar A, Cui Q, Chavan D, Dominiak K . New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res. 2009; 26(8):1874-80. PMC: 3792798. DOI: 10.1007/s11095-009-9900-8. View

16.

Wang D, Veena M, Stevenson K, Tang C, Ho B, Suh J . Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res. 2008; 14(19):6228-36. DOI: 10.1158/1078-0432.CCR-07-5177. View

17.

Adams B, Cai J, Armstrong J, Herold M, Lu Y, Sun A . EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs. 2005; 16(3):263-75. DOI: 10.1097/00001813-200503000-00005. View

18.

Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P . Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998; 64(4):353-6. DOI: 10.1055/s-2006-957450. View

19.

Robinson T, Ehlers T, Hubbard IV R, Bai X, Arbiser J, Goldsmith D . Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorg Med Chem Lett. 2002; 13(1):115-7. DOI: 10.1016/s0960-894x(02)00832-6. View

20.

Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A . Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther. 2006; 5(10):2563-71. DOI: 10.1158/1535-7163.MCT-06-0174. View